Company / Capital Returned to Shareholders
Harmony Biosciences Holdings, Inc. Capital Returned to Shareholders History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$100.0M
FY2023
5-year range
$167.0K / $100.0M
FY2020-FY2023
Trend
-
vs FY2022
Sector context
#22 of 52
Health Care
What the data says
Capital Returned to Shareholders changed +59780% YoY in FY2023, a notable deviation from the 2-year average annual change of +29890%.
Based on SEC 10-K filings.
$100M in FY2023.
Improved from $167,000 to $100M over the past 3 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- +742.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#22 of 52 in Health CareTop 42% of 52This company $100.0M Sector average $1.3B
▼
-92.5% below sector average
Key checks
Key Insights
- 3-year CAGR of +742.9%, indicating consistent growth.
- Ranks #22 out of 52 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $100.0M | - |
| FY2022 | - | - |
| FY2021 | $167.0K | +0.0% |
| FY2020 | $167.0K | - |
| FY2019 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026